Second-line gastric cancer is an unmet medical need, but the phase-3 trial in question was limited to patients in Japan, Korea and Taiwan. So, data on non-Asian patients will probably be needed for FDA approval in this indication, but Opdivo will almost certainly get a label expansion in the countries mentioned above and perhaps other countries in Asia.
Normally, the inclusion or exclusion of such boilerplate language is a pretty reliable signal. However, for a US-based company, getting feedback from regulators in Japan, Korea, and Taiwan may be more cumbersome than getting feedback from the FDA, so BMY may be reticent about commenting on regulatory plans.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.